http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3878980-D1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56 |
| filingDate | 1988-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1993-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56bfed5a2e3f16e63d0fcfedd9d64601 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71b470c902493fc4e87d181956a0adfb |
| publicationDate | 1993-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-3878980-D1 |
| titleOfInvention | METHOD FOR DETECTING THE ANTIAGGREGATORY EFFECT OF VASOACTIVE SUBSTANCES, SPECIFICALLY OF PHOSPHODIESTERASE AND / OR CYCLOOXYGENASE INHIBITORS. |
| abstract | In vitro detection of the antiaggregatory activity of phosphodiesterase inhibitors (A) and/or cyclooxygenase inhibitors (B) comprises (1) adding (A) and/or (B) to a sample of blood (where these are not already present, opt. in metabolised form, from a preliminary application); (2) opt. sepn. of erythrocytes and leucocytes and (3) initiation, pref. by adding an inducer, and measurement of thrombocyte aggregation. The new feature is that before (or at the latest simultaneously with) initiation of aggregation, the sample is treated with (a) (A) or (B), only if not added in step (1), and (b) a prostaglandin (C), so that step (3) is carried out in presence of all 3 of (A), (B) and (C). The concns. used are 10nM-1mM (esp. 1-1000 microns) for (A) and (B), and 0.1nM-1 microm (pref. 1-100nM) for (C), and aggregation is initiated with arachidonic acid or collagen. The measurement is esp. done optically on a plasma sample. (A) are xanthine or pyrimido-pyrimidine cpds., esp. pentoxifyllin (I); pyrimidamol (IIa) or mopidamol (IIb). (B) are O-acetylsalicylic acid (pref.), indomethacin, metamizole, ibuprofen, or their prodrugs, biologically-active metabolites or salts. (C) are PGI2, PGD2 or more pref. PGE, or 6-Keto-PGE1, or their salts or derivs. |
| priorityDate | 1987-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.